Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis

PURPOSE: Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ann Surg Oncol
Main Authors: Newhook, Timothy E., Lindberg, James M., Adair, Sara J., Kim, Alison J., Stelow, Edward B., Rahma, Osama E., Parsons, J. Thomas, Bauer, Todd W.
格式: Artigo
語言:Inglês
出版: 2016
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637098/
https://ncbi.nlm.nih.gov/pubmed/26847682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-016-5116-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍